Here we proposed the most recent innovations in the use of Breast Specific Gamma Imaging with ⁹⁹mTc-sestamibi for the management of breast cancer patients. To this end, we reported the recent discoveries concerning: a) the implementation of both instrumental devices and software, b) the biological mechanisms involved in the ⁹⁹mTc-sestamibi uptake in breast cancer cells, c) the evaluation of Breast Specific Gamma Imaging with ⁹⁹mTc-sestamibi as predictive markers of metastatic diseases. In this last case, we also reported preliminary data about the capability of Breast Specific Gamma Imaging with ⁹⁹mTc-sestamibi to identify breast cancer lesions with high propensity to form bone metastatic lesions due to the presence of Breast Osteoblast-Like Cells.

在这里，我们提出了使用⁹⁹ mTc-sestamibi 进行乳腺特异性伽马成像治疗乳腺癌患者的最新创新。为此，我们报告了有关以下方面的最新发现：a）仪器设备和软件的实施，b）乳腺癌细胞中^{99 mTc-sestamibi 摄取所涉及的生物学机制，c）乳腺特异性伽马成像评估99} mTc-sestamibi 作为转移性疾病的预测标志物。在最后一个案例中，我们还报告了关于^{99的乳腺特异性伽马成像能力的初步数据。}mTc-sestamibi 可识别由于乳腺成骨细胞样细胞的存在而容易形成骨转移性病变的乳腺癌病变。